AC
BIO icon

Almitas Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Almitas Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,254
Closed -$8.43M – 131
2026
Q1 		$8.43M Buy
+30,254
New +$8.71M 1.91% 9

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Almitas Capital's BIO Position: Q2 2026 in Review

Almitas Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 30,254 shares — an estimated $8.43M sold.

Almitas Capital first reported a position in BIO in Q1 2026 and held it in 1 quarter. The position peaked at $8.43M in Q1 2026. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Almitas Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Almitas Capital sold 30,254 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $8.43M.
  • Almitas Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and held it in 1 quarter.
  • Almitas Capital's Bio-Rad Laboratories Class A position peaked at $8.43M in Q1 2026.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Almitas Capital's 13F filing for Q2 2026, filed 17 Aug 2026.